Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer in China

NCT06640049 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06640049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06640049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer in China
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 17, 2024
Completion date
April 15, 2031
Enrollment
23 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, rectal